225 related articles for article (PubMed ID: 36863287)
1. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
2. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366561
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
4. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.
Demant J; Krohn-Dehli L; Van der Veen J; Øvrehus A; Lazarus JV; Weis N
Int J Drug Policy; 2023 Nov; 121():104185. PubMed ID: 37774576
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
6. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
[TBL] [Abstract][Full Text] [Related]
7. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
9. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
11. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.
Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
Int J Drug Policy; 2023 Mar; 113():103959. PubMed ID: 36758335
[TBL] [Abstract][Full Text] [Related]
12. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
13. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
[TBL] [Abstract][Full Text] [Related]
14. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
15. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
[TBL] [Abstract][Full Text] [Related]
17. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
[TBL] [Abstract][Full Text] [Related]
18. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
19. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ;
Int J Drug Policy; 2018 Dec; 62():94-103. PubMed ID: 30384028
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
